LRRK2 and Parkinson disease: Several favorable candidate inhibitors have been developed for the experimental control of PD based on the kinase activity of LRRK2, such as LRRK2-IN-1 [35], CZC-54252 and CZC-25146 [36], GSK2578215A [37] etc. The LRRK2 inhibitor, PF-06447475, effectively attenuates α-synuclein-induced dopaminergic neurodegeneration [38].